#USA #Houston #Protein Synthesis #Sino Biological #XPressMAX™

Sino Biological Unveils the Innovative XPressMAX™ Cell-Free Protein Synthesis Kit

Sino Biological, Inc., a global leader in recombinant technology, recently announced the launch of its groundbreaking XPressMAX™ Cell-Free Protein Synthesis Kit. This innovative solution is set to significantly enhance high-throughput antibody drug discovery processes powered by artificial intelligence, aiming to streamline and accelerate research in this pivotal field.

A Leap Forward in Research Tools

Unveiled amidst an ever-evolving biotechnology landscape, the XPressMAX™ kit promises unprecedented speed in protein synthesis. Designed to facilitate in vitro production of target proteins and antibodies without the constraints of traditional cell expression systems, it integrates seamlessly with AI-driven screening platforms. Researchers can now identify and optimize antibody candidates more efficiently, drastically reducing development time and costs.

With the XPressMAX™, Sino Biological has harnessed the advantages of cell-free synthesis technology to provide a highly efficient alternative. The kit is based on an E. coli lysate and is equipped with essential transcription and translation components, allowing direct synthesis of proteins from either plasmid or PCR templates. Specifically tailored for antibody drug discovery, XPressMAX™ supports the rapid expression and validation of various formats, including VHHs, scFvs, Fabs, and minibroteins.

Accelerated Processes and High Success Rates

The highlights of the XPressMAX™ kit are impressive, featuring:

• - Ultra-Fast Synthesis: Achieving protein synthesis within just three hours.
• - High Success Rate: An outstanding success rate exceeding 99%.
• - Complex Disulfide Bond Formation: Ensuring native folding and bioactivity without the need for additional enhancers.

Dr. Rob Burgess, the Chief Business Officer at Sino Biological US, Inc., emphasized the significance of this advancement, stating, "XPressMAX™ marks a major step forward for research tools and reagents in the next generation of therapeutic discovery. Through rapid and reliable protein expression combined with intelligent screening, we are helping our partners drastically reduce antibody discovery timelines without compromising quality."

Echoing this sentiment, Dr. Jie Zhang, the CEO of Sino Biological, remarked, "AI is revolutionizing antibody screening, but it requires expression systems that can match its speed and throughput. With XPressMAX™, we can express challenging proteins rapidly and successfully in just three hours."

Enhanced Screening Platforms

Sino Biological's commitment to innovation is evident as they have successfully established a high-throughput, cell-free platform, validating over 2,000 scFv/VHH molecules within a span of 3 to 4 weeks. This rapid iteration process empowers researchers by providing them with timely data to inform their next steps.

Requesting Samples and More Information

Researchers interested in exploring the XPressMAX™ Cell-Free Protein Synthesis Kit are encouraged to visit Sino Biological’s website for more details or to request a free sample of the product.

About Sino Biological

Sino Biological is an international provider of reagents and CRO services, specializing in recombinant protein production and antibody development. With its Center for Bioprocessing (C4B) based in Houston, Texas, and SignalChem Biotech in Canada, the company offers tailored solutions to meet a diverse range of research needs worldwide. Serving researchers across over 90 countries, Sino Biological adheres to a stringent quality management system that ensures high-quality products and services.

For further inquiries about Sino Biological and its offerings, you can contact them at [email protected] or explore the website for a wealth of information about their products and services.